EPS for Adamis Pharmaceuticals Corporation (ADMP) Expected At $-0.18

July 14, 2018 - By Matthew Richard

Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) Logo

Analysts expect Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) to report $-0.18 EPS on August, 13.They anticipate $0.01 EPS change or 5.26 % from last quarter’s $-0.19 EPS. After having $-0.23 EPS previously, Adamis Pharmaceuticals Corporation’s analysts see -21.74 % EPS growth. The stock increased 3.21% or $0.125 during the last trading session, reaching $4.025. About 292,090 shares traded. Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) has risen 14.47% since July 14, 2017 and is uptrending. It has outperformed by 1.90% the S&P500.

Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) Ratings Coverage

Among 4 analysts covering Adamis Pharmaceuticals (NASDAQ:ADMP), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Adamis Pharmaceuticals had 4 analyst reports since March 23, 2018 according to SRatingsIntel. FBR Capital maintained Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) on Monday, May 14 with “Buy” rating. The rating was maintained by Maxim Group with “Buy” on Monday, May 14. B. Riley & Co maintained Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) rating on Friday, March 23. B. Riley & Co has “Buy” rating and $6.25 target.

Adamis Pharmaceuticals Corporation, a specialty biopharmaceutical company, develops and commercializes products in the therapeutic areas of allergy and respiratory disease in the United States. The company has market cap of $134.39 million. The companyÂ’s specialty pharmaceutical product candidates comprise Epinephrine Injection pre-filled syringe for use in the emergency treatment of acute allergic reactions, including anaphylaxis; dry powder inhaler products consisting of albuterol (APC-2000) and fluticasone (APC-4000) for the treatment of bronchospasm and asthma; and beclomethasone (APC-1000), a metered dose inhaler product for the asthma, as well as APC-1000 and APC-5000 for the treatment of asthma and chronic obstructive pulmonary disease. It currently has negative earnings. It also operates a 503B drug outsourcing facility that provides prescription compounded medications to patients, physician clinics, hospitals, surgery centers, and other clients in the United States.

More notable recent Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) news were published by: Seekingalpha.com which released: “What Is Adamis Worth?” on July 03, 2018, also Streetinsider.com with their article: “Pre-Open Movers 07/02: (ADMP) (VMW) (TSLA) Higher; (MDXG) (MLCO) (LVS) Lower (more…)” published on July 02, 2018, Seekingalpha.com published: “Time Is Nearly Up For Adamis” on June 19, 2018. More interesting news about Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) were released by: Nasdaq.com and their article: “Mid-Morning Market Update: Markets Open Lower; Randa Proposes To Acquire Perry Ellis” published on July 02, 2018 as well as Seekingalpha.com‘s news article titled: “Rounds Report: Adamis Rallied Due To A Commercialization Partnership” with publication date: July 05, 2018.

Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.